SG11202007898XA - Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof - Google Patents
Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereofInfo
- Publication number
- SG11202007898XA SG11202007898XA SG11202007898XA SG11202007898XA SG11202007898XA SG 11202007898X A SG11202007898X A SG 11202007898XA SG 11202007898X A SG11202007898X A SG 11202007898XA SG 11202007898X A SG11202007898X A SG 11202007898XA SG 11202007898X A SG11202007898X A SG 11202007898XA
- Authority
- SG
- Singapore
- Prior art keywords
- hhla2
- kir3dl3
- antibodies
- receptor
- hhla2 receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862654068P | 2018-04-06 | 2018-04-06 | |
PCT/US2019/026034 WO2019204057A1 (en) | 2018-04-06 | 2019-04-05 | Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007898XA true SG11202007898XA (en) | 2020-10-29 |
Family
ID=68239919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007898XA SG11202007898XA (en) | 2018-04-06 | 2019-04-05 | Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210115144A1 (en) |
EP (1) | EP3773658A4 (en) |
JP (2) | JP7429192B2 (en) |
KR (1) | KR20210007959A (en) |
CN (1) | CN112153977A (en) |
AU (1) | AU2019257249A1 (en) |
BR (1) | BR112020015999A2 (en) |
CA (1) | CA3091859A1 (en) |
IL (1) | IL276746A (en) |
MX (1) | MX2020010094A (en) |
RU (1) | RU2020136055A (en) |
SG (1) | SG11202007898XA (en) |
WO (1) | WO2019204057A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114867493A (en) * | 2019-10-04 | 2022-08-05 | 阿尔伯特爱因斯坦医学院 | KIR3DL3 is an inhibitory receptor of the immune system and uses thereof |
US20230178239A1 (en) * | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
CN112946268B (en) * | 2020-12-29 | 2022-12-27 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Application of HHLA2 as prognostic marker in preparation of liver cancer prognosis prediction kit |
BR112023014826A2 (en) * | 2021-01-28 | 2023-10-03 | Nextpoint Therapeutics Inc | HHLA2 BINDING AGENTS WITH NEW ACTIVITY |
AU2022301125A1 (en) * | 2021-07-01 | 2024-01-04 | Albert Einstein College Of Medicine | Compositions and methods for inhibiting the expression of tmigd2 |
CN113621068B (en) * | 2021-10-11 | 2022-01-07 | 上海恒润达生生物科技股份有限公司 | Antibody or antigen binding fragment thereof specifically binding to CD276, and preparation method and application thereof |
WO2023138579A1 (en) * | 2022-01-21 | 2023-07-27 | 和铂医药美国股份有限公司 | Anti-b7-h7 antibody or antigen-binding fragment thereof, and preparation method therefor and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100120246A (en) * | 2001-11-14 | 2010-11-12 | 센토코 오르토 바이오테크 인코포레이티드 | Anti-il-6 antibodies, compositions, methods and uses |
EP3381937A3 (en) * | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
CN103906535B (en) * | 2011-08-15 | 2017-07-14 | 芝加哥大学 | The composition related to the antibody of staphylococcal protein A and method |
WO2014133728A2 (en) * | 2013-03-01 | 2014-09-04 | Albert Einstein College Of Medicine Of Yeshiva University | Hhla2 as a novel inhibitor of human immune system and uses thereof |
AU2014268298B2 (en) * | 2013-05-24 | 2019-01-17 | Medlmmune, Llc | Anti-B7-H5 antibodies and their uses |
WO2015187359A1 (en) * | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
AR109279A1 (en) * | 2016-08-03 | 2018-11-14 | Achaogen Inc | ANTI-PLAZOMYCIN ANTIBODIES AND METHODS OF USE OF THE SAME |
-
2019
- 2019-04-05 AU AU2019257249A patent/AU2019257249A1/en active Pending
- 2019-04-05 CN CN201980031870.6A patent/CN112153977A/en active Pending
- 2019-04-05 EP EP19789172.4A patent/EP3773658A4/en active Pending
- 2019-04-05 SG SG11202007898XA patent/SG11202007898XA/en unknown
- 2019-04-05 MX MX2020010094A patent/MX2020010094A/en unknown
- 2019-04-05 RU RU2020136055A patent/RU2020136055A/en unknown
- 2019-04-05 WO PCT/US2019/026034 patent/WO2019204057A1/en unknown
- 2019-04-05 CA CA3091859A patent/CA3091859A1/en active Pending
- 2019-04-05 KR KR1020207030319A patent/KR20210007959A/en active Search and Examination
- 2019-04-05 BR BR112020015999-9A patent/BR112020015999A2/en unknown
- 2019-04-05 US US17/044,493 patent/US20210115144A1/en active Pending
- 2019-04-05 JP JP2020554272A patent/JP7429192B2/en active Active
-
2020
- 2020-08-17 IL IL276746A patent/IL276746A/en unknown
-
2024
- 2024-01-26 JP JP2024009992A patent/JP2024032865A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019204057A1 (en) | 2019-10-24 |
CN112153977A (en) | 2020-12-29 |
JP2024032865A (en) | 2024-03-12 |
EP3773658A4 (en) | 2022-04-27 |
AU2019257249A1 (en) | 2020-10-15 |
CA3091859A1 (en) | 2019-10-24 |
JP7429192B2 (en) | 2024-02-07 |
BR112020015999A2 (en) | 2020-12-15 |
US20210115144A1 (en) | 2021-04-22 |
RU2020136055A (en) | 2022-05-06 |
MX2020010094A (en) | 2021-01-15 |
IL276746A (en) | 2020-10-29 |
KR20210007959A (en) | 2021-01-20 |
JP2021520208A (en) | 2021-08-19 |
RU2020136055A3 (en) | 2022-05-06 |
EP3773658A1 (en) | 2021-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274921A (en) | Bcma-targeting chimeric antigen receptor, and uses thereof | |
IL268588A (en) | Anti-gprc5d antibodies, compositions comprising same and uses thereof | |
IL264654B1 (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
IL276746A (en) | Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof | |
EP3283110A4 (en) | Antibodies directed against interleukin 36 receptor (il-36r) | |
IL291299A (en) | Anti-tnfr2 antibodies, composotions comprising same and uses thereof | |
IL283754A (en) | Anti-claudin antibodies, compositions comprising same and uses thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
GB201614162D0 (en) | Antibodies, uses thereof and conjugates thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof | |
SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
IL283890A (en) | Anti-periostin antibodies and uses thereof | |
EP3341004A4 (en) | Mrka polypeptides, antibodies, and uses thereof | |
IL279790A (en) | Anti-l1cam antibodies and uses thereof |